News | Cardio-oncology | June 15, 2017

New Echo Protocol Aids Monitoring Children’s Heart Abnormalities Due to Chemotherapy

Pediatric echo protocols for cardio-oncology cardiotoxicity exams.

 June 15, 2017 – Children who have suffered from cancer may also have lasting side effects from the drugs used in the treatment of cancer, or chemotherapy-induced cardiotoxicity. The use of anthracyclines, very effective chemotherapy drugs, can be limited by development of cardiotoxicity, which has been traditionally monitored by echocardiography. A recent study at Children’s Hospital of Michigan used real-time 3-D imaging to detect early functional abnormalities associated with cardiotoxicity in the hearts of children following anthracycline chemotherapy.

“In our research study, we evaluated heart function of children who had completed anthracycline chemotherapy for cancer using a real-time 3-D echocardiography technique,” said lead author Sanjeev Aggarwal, M.D., pediatric cardiologist at The Children's Hospital of Michigan and Wayne State University School of Medicine, Detroit, Mich. “We found that, an average of five years after chemotherapy, asymptomatic children who had normal volume of the ventricles of the heart and normal ejection fraction, still had significant left ventricular dyssynchrony on the 3D echo. Dyssynchrony is a difference in contraction timing of various heart segments. The ability of this noninvasive bedside technique to diagnose cardiac dysfunction in the subclinical stage, even before abnormalities can be detected on a conventional echo, may open the possibilities of timely intervention and prevention of progression of the cardiotoxicity. Currently, when cardiotoxicity is detected, it can be irreversible. Further longitudinal studies are needed.” 
 
Researchers on the study, Left Ventricular Dyssynchrony and Real Time 3-D Echocardiogram in Children Following Chemotherapy include Sanjeev Aggarwal, M.D., and Gilda Kadiu, RDCS from Children's Hospital of Michigan.
 
Aggarwal presented a poster based on this research during the recent ASE 28th Annual Scientific Sessions. 

Watch the VIDEO "Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging."  This is an interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health Research Institute and assistant professor of medicine (cardiology) at Georgetown University, at the American Society of Echocardiography (ASE) 2016 annual meeting. Asch discusses the technology used for cardio-oncology cardiotoxcity assessments and how to set up these types of collaborative programs between oncology and cardiology. For more information, read the article Assessing Cardiotoxicity Due to Cancer Therapy.

Read the related article “Assessing Cardiotoxicity Due to Cancer Therapy.” 

For more information: ASEcho.org
 

Related Content

ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound| October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
Toshiba Medical's Portable Ultrasound Used in Second Pediatric Mission in Tanzania
News | Ultrasound Imaging| October 05, 2017
October 5, 2017 — To provide lifesaving surgical care for sick children in one of the most underserved countries, 13
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
GE’s blood speckle imaging (BSI) software shows the flow of blood cells’ trajectories. It is a form of blood vector flow imaging.

GE’s blood speckle imaging (BSI) software offers the ability to view a graphical representation of the blood cells’ trajectories.

News | Cardiovascular Ultrasound| September 01, 2017
Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advance
Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init